Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus.

Abstract

We report on 2 critically ill patients with pneumonitis and acute respiratory distress syndrome due to pandemic (H1N1) 2009 influenza A virus who were treated with intravenous zanamivir and had favorable clinical outcomes. Zanamivir given intravenously may be a therapeutic option in patients with critical illness and mechanical ventilation.

• Authors: Georg Härter, Oliver Zimmermann, Ludwig Maier, Axel Schubert, Thomas Mertens, Peter Kern, Jochen Wöhrle
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 50 Issue 9 Pg. 1249-51 (May 01 2010) ISSN: 1537-6591 [Electronic] United States
• PMID: 20367227 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antiviral Agents
• Zanamivir

Topics

• Adult
• Antiviral Agents (administration & dosage, therapeutic use)
• Critical Illness
• Humans
• Influenza A Virus, H1N1 Subtype (isolation & purification)
• Influenza, Human (complications, drug therapy, virology)
• Injections, Intravenous
• Male
• Middle Aged
• Pneumonia (drug therapy)
• Respiratory Distress Syndrome (drug therapy)
• Treatment Outcome
• Zanamivir (administration & dosage, therapeutic use)